↓ Skip to main content

Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation

Overview of attention for article published in Critical Care, April 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (59th percentile)

Mentioned by

twitter
43 X users
patent
1 patent

Citations

dimensions_citation
41 Dimensions

Readers on

mendeley
101 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
Published in
Critical Care, April 2016
DOI 10.1186/s13054-016-1275-8
Pubmed ID
Authors

Oliver Grottke, James Aisenberg, Richard Bernstein, Patrick Goldstein, Menno V. Huisman, Dara G. Jamieson, Jerrold H. Levy, Charles V. Pollack, Alex C. Spyropoulos, Thorsten Steiner, Gregory J. del Zoppo, John Eikelboom

Abstract

Dabigatran is effective in decreasing the risk of ischaemic stroke in patients with atrial fibrillation. However, like all anticoagulants, it is associated with a risk of bleeding. In cases of trauma or emergency surgery, emergency reversal of dabigatran-induced anticoagulation may be required. A specific reversal agent for dabigatran, idarucizumab, has been approved by the US Food and Drug Administration. Alternative reversal agents are available, such as prothrombin complex concentrates (PCCs) and activated PCCs (aPCCs). In this review we evaluate the role of PCCs and aPCCs in the reversal of dabigatran anticoagulation and consider which tests are appropriate for monitoring coagulation in this setting. Pre-clinical studies, small clinical studies and case reports indicate that PCCs and aPCCs may be able to reverse dabigatran-induced anticoagulation in a dose-dependent manner. However, dosing based on coagulation parameters can be difficult because available assays may not provide adequate sensitivity and specificity for measuring anticoagulation induced by dabigatran or the countering effects of PCCs/aPCCs. In addition, PCCs or aPCCs can potentially provoke thromboembolic complications. Despite these limitations and the fact that PCCs and aPCCs are not yet licensed for dabigatran reversal, their use appears to be warranted in patients with life-threatening haemorrhage if idarucizumab is not available.

X Demographics

X Demographics

The data shown below were collected from the profiles of 43 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Slovenia 1 <1%
Unknown 100 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 17 17%
Other 13 13%
Student > Ph. D. Student 11 11%
Student > Postgraduate 7 7%
Professor 7 7%
Other 31 31%
Unknown 15 15%
Readers by discipline Count As %
Medicine and Dentistry 57 56%
Pharmacology, Toxicology and Pharmaceutical Science 9 9%
Biochemistry, Genetics and Molecular Biology 2 2%
Arts and Humanities 2 2%
Agricultural and Biological Sciences 2 2%
Other 5 5%
Unknown 24 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 August 2018.
All research outputs
#1,456,901
of 25,374,647 outputs
Outputs from Critical Care
#1,279
of 6,554 outputs
Outputs of similar age
#24,118
of 312,662 outputs
Outputs of similar age from Critical Care
#45
of 110 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,554 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.8. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,662 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 110 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.